pSivida drug delivery data
This article was originally published in The Gray Sheet
Executive Summary
Preliminary data from a four-patient safety trial suggest that pSivida's BrachySil nanotechnology liver cancer treatment device achieves 80% tumor regression by volume, with no product-related adverse events. A dose-profiling study will begin shortly, followed by a multicenter pivotal trial in Europe and the U.S. The Australian firm aims to license the drug-delivery device to a top pharma firm during 2005 (1"The Gray Sheet" Feb. 14, 2005, p. 28)...